文献速递血栓与止血

Concizumab 用于无抑制物血友病 A/B 患者的 56 周 cut-off 结果:3 期 explorer8 研究

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study.
PubMed 文献 · Blood Adv · 2026-01-01

explorer8 是前瞻性、多中心、开放标签 3 期研究,评估每日一次皮下注射 concizumab 预防治疗无抑制物血友病 A/B 的长期疗效与安全性。56 周 cut-off 时,concizumab 组治疗性自发出血和创伤性出血的年化出血率中位数维持较低水平(HA 1.7,HB 2.8),药代动力学稳定,未发现新的安全性问题。

要点

  • concizumab 在无抑制物 HA/HB 患者中维持较低年化出血率(HA 1.7,HB 2.8)
  • concizumab 血浆浓度稳定,56 周内未发现新的安全性问题
  • 研究为开放标签设计,组 3/4 为非随机分配 concizumab

核心结论

  • 在 56 周 cut-off 时,concizumab 在无抑制物血友病 A/B 患者中显示出长期疗效,且被认为安全、耐受良好。

研究设计与样本

  • 前瞻性、多中心、开放标签 3 期 explorer8 研究,纳入 ≥12 岁男性血友病 A/B 患者。
  • 全分析集 148 例:组 1 随机不接受预防治疗 21 例(HA 9 例,HB 12 例),组 2 随机接受 concizumab 42 例(HA 18 例,HB 24 例),组 3/4 非随机接受 concizumab 85 例(HA 55 例,HB 30 例)。
  • 56 周 cut-off 定义为组 2 至组 4 所有患者完成 56 周访视或永久终止治疗时。
  • 组 1 中 17 例患者在治疗 ≥24 周后转为 concizumab。
  • 试验注册号 NCT04082429。

主要发现

  • 接受 concizumab 的患者在 56 周 cut-off 时维持较低的治疗性自发出血和创伤性出血年化出血率中位数:HA 1.7(IQR 0.0-4.5),HB 2.8(IQR 0.0-6.4),与 32 周 cut-off 结果一致。
  • Concizumab 血浆浓度保持稳定。
  • 未发现新的安全性问题。

临床怎么用

  • Concizumab 可作为无抑制物血友病 A/B 患者每日一次皮下预防治疗的选项,56 周数据支持其长期疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Concizumab is a novel nonfactor replacement therapy for once-daily subcutaneous prophylactic treatment of hemophilia A/B (HA/HB) with and without inhibitors. Concizumab was superior to on-demand treatment in patients with HA/HB without inhibitors in the prospective, multicenter, open-label phase 3 explorer8 study. Here, longer-term efficacy and safety results from the start of the study up to the 56-week cutoff are presented. Males aged ≥12 years with HA/HB were randomized 1:2 to no prophylaxis (group 1) or concizumab (group 2) or allocated to concizumab (groups 3 and 4). Assessments at the 56-week cutoff included efficacy, pharmacokinetics/pharmacodynamics, and safety. The 56-week cutoff was defined as when all patients in groups 2 to 4 had completed the visit at 56 weeks or permanently discontinued treatment. Of 148 patients in the full analysis set, 21 were randomized to no prophylaxis (group 1: HA, n = 9; HB, n = 12), 42 to concizumab (group 2: HA, n = 18; HB, n = 24), and 85 to the nonrandomized concizumab groups (groups 3 and 4: HA, n = 55; HB, n = 30). After ≥24 weeks of treatment, 17 patients in group 1 switched to concizumab. Low median annualized bleeding rates for treated spontaneous and traumatic bleeding episodes were maintained at the 56-week cutoff in patients receiving concizumab (HA, 1.7 [interquartile range (IQR), 0.0-4.5]; HB, 2.8 [IQR, 0.0-6.4]), consistent with 32-week cutoff results. Concizumab plasma concentration remained stable, with no new safety concerns. Concizumab showed longer-term efficacy in patients with HA/HB at the 56-week cutoff and was considered safe and well tolerated. This trial was registered at www.clinicaltrials.gov as #NCT04082429.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Young G, Angchaisuksiri P, Apte S, et al. Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study. Blood Adv. 2026. PMID: 42341325. doi:10.1182/bloodadvances.2026019931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。